We currently do not have sufficient information about the CEO.
Key information
Vin Menon
Chief executive officer
n/a
Total compensation
CEO salary percentage
n/a
CEO tenure
less than a year
CEO ownership
n/a
Management average tenure
less than a year
Board average tenure
2.7yrs
Recent management updates
Recent updates
CEO
Vin Menon (48 yo)
less than a year
Tenure
Dr. Vinod Menon, also known as Vin, served as Chief Executive Officer of Apimeds Pharmaceuticals US, Inc. since December 2025 until May 04, 2026 and serves as its Co-Chief Executive Officer since May 04, 2...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Erik Emerson
President
no data
US$2.25m
no data
Erick Frim
Chief Financial Officer
less than a year
US$20.26k
no data
Vinod Menon
Founder & Co-CEO
less than a year
no data
no data
Sungjoon Chae
Co-Chief Executive Officer
less than a year
no data
no data
Sandeep Yadav
Chief Operating Officer
no data
no data
no data
Amardeep Singh
Chief Technology Officer
no data
no data
no data
0.08yrs
Average Tenure
51.5yo
Average Age
Experienced Management: APUS's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.
Board Members
Name
Position
Tenure
Compensation
Ownership
Bennett Weintraub
Independent Director
2.7yrs
US$39.72k
no data
Elona Kogan
Independent Director
1.7yrs
US$42.72k
no data
Carol O'Donnell
Independent Director
2.7yrs
US$45.72k
no data
Jakap Koo
Director
2.7yrs
US$29.72k
no data
Christopher M. Kim
Chief Medical Officer & Chairman
no data
US$629.05k
no data
2.7yrs
Average Tenure
65yo
Average Age
Experienced Board: APUS's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/04 05:54
End of Day Share Price
2026/06/04 00:00
Earnings
N/A
Annual Earnings
N/A
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Apimeds Pharmaceuticals US, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.